Our Technology

Our Technology

Trailblazing programs have demonstrated that diseases of retinal degeneration can be treated with cell therapy, but the current programs all have significant limitations that affect clinical applications.

We believe that age-related macular degeneration (AMD), Retinitis Pigmentosa and Stargardt’s Disease will eventually be addressed with a progenitor cell that can differentiate into Retinal Pigment Epithelial cells (RPE) and Photoreceptors.   Our innovative cell product aims for all three of these conditions.  

Alpine BioTherapeutics’ patent protected technology is enable a simple, short and efficient manufacturing process to produce unlimited supply of iPSC-derived retinal stem cells/progenitors under the GMP condition.  

The mechanism of action (MOA) of retinal progenitor engraftment is not fully understood, but it is believed to work through two main modes: 1) Retinal stem cells or progenitors differentiate and replace the diseased photoreceptors (light-sensing cells) and RPE cells and repair the damaged retinal tissue; 2) the transplanted cells release exosomes and soluble factors such as neurotrophic factors, cytokines, chemokines and growth factors, which act in a paracrine or endocrine manner and facilitate retinal tissue healing.

Connect with us

10355 Science Center Drive, Suite 130, San Diego, CA 92121

  • dummy info@alpinebt.com


Enter your email and we'll send you more information